by Janna Manjelievskaia, Dara Erck, Samina Piracha et al.
Trans R Soc Trop Med Hyg (2016) 110 (3): 186-191. – This article appears in: Special issue: Implementing the End TB Strategy and the SDGs
In 2014, an estimated 9.6 million TB cases and 1.5 million deaths occurred worldwide; 3.3% of these cases resulted from multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) strains. These figures underestimate the economic burden associated with MDR-TB and XDR-TB, as the cost of treating disease caused by these strains can be 9–25 times higher than treating drug-susceptible TB. Developing new drugs, improved diagnostics and new TB vaccines are critical components of a strategy to combat TB in general, and drug-resistant TB in particular.